Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 14 unusual trades.
金融巨頭對再生元製藥公司做出了明顯的看淡動作。我們對再生元製藥公司（NASDAQ: REGN）期權歷史的分析表明，共有14宗不尋常的交易。
Delving into the details, we found 14% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $721,270, and 10 were calls, valued at $1,045,138.
詳細了解後發現，14%的交易者看好該股，而50%則表現出看淡的傾向。我們發現，所有交易中有4單看跌期權，價值721,270美元，有10單看漲期權，價值1,045,138美元。
Projected Price Targets
預計價格目標
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $960.0 to $1280.0 for Regeneron Pharmaceuticals over the last 3 months.
考慮到這些合同的成交量和持倉量，近3個月來龐大的交易者似乎一直瞄準再生元製藥公司的價格區間在$960.0到$1280.0之間。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Regeneron Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Regeneron Pharmaceuticals's significant trades, within a strike price range of $960.0 to $1280.0, over the past month.
檢查成交量和持倉量可以提供關於股票研究的重要見解。這些信息對於評估再生元製藥公司在特定行權價格的期權的流動性和利益水平至關重要。下面，我們介紹過去一個月內再生元製藥公司重要交易的看跌和看漲期權的成交量和持倉量趨勢。這些期權在行權價格範圍爲$960.0至$1280.0之間。
Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
再生元製藥公司過去30天的期權成交量和持倉量
Significant Options Trades Detected:
檢測到重大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | CALL | TRADE | NEUTRAL | 01/17/25 | $160.3 | $152.0 | $156.6 | $980.00 | $454.1K | 200 | 0 |
| REGN | PUT | TRADE | BEARISH | 06/20/25 | $99.0 | $91.5 | $96.0 | $1100.00 | $384.0K | 3 | 0 |
| REGN | PUT | TRADE | NEUTRAL | 12/18/26 | $112.0 | $102.0 | $107.0 | $1040.00 | $214.0K | 0 | 0 |
| REGN | CALL | TRADE | BEARISH | 06/20/25 | $58.0 | $55.0 | $55.0 | $1280.00 | $165.0K | 19 | 0 |
| REGN | PUT | TRADE | BEARISH | 01/17/25 | $33.5 | $27.3 | $31.3 | $980.00 | $90.7K | 117 | 0 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 再生元製藥公司 | 看漲 | 交易 | 中立 | 01/17/25 | $160.3 | 152.0美元 | $156.6 | 980.00美元。 | $454.1K | 200 | 0 |
| 再生元製藥公司 | 看跌 | 交易 | 看淡 | 06/20/25 | $99.0 | $91.5 | $96.0 | $1100.00 | $384.0K | 3 | 0 |
| 再生元製藥公司 | 看跌 | 交易 | 中立 | 12/18/26 | $112.0 | $102.0 | $107.0 | $1040.00 | $214.0K | 0 | 0 |
| 再生元製藥公司 | 看漲 | 交易 | 看淡 | 06/20/25 | $58.0 | $55.0 | $55.0 | $1280.00 | $165.0K | 19 | 0 |
| 再生元製藥公司 | 看跌 | 交易 | 看淡 | 01/17/25 | $33.5 | $27.3 | $31.3 | 980.00美元。 | $90.7K | 117 | 0 |
About Regeneron Pharmaceuticals
關於再生元製藥公司
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
再生元製藥公司發現、開發和商業化對抗眼部疾病、心血管疾病、癌症和炎症的藥物。該公司擁有幾種上市產品，包括用於溼性年齡相關性黃斑變性和其他眼病的艾立雅；用於降低低密度脂蛋白膽固醇的普遍；在免疫學上的杜派珊；在腫瘤學上的力比多；以及在類風溼性關節炎上的科瓦匝。再生元製藥公司還與賽諾菲安萬特、其他合作伙伴和獨立開發單克隆和雙特異性抗體，並有較早階段的合作伙伴關係，爲管道帶來新的技術，包括RNAi（Alnylam）和CRISPR基因編輯（Intellia）。
Following our analysis of the options activities associated with Regeneron Pharmaceuticals, we pivot to a closer look at the company's own performance.
在分析再生元製藥公司的期權活動後，我們轉而更近距離地審視公司本身的表現。
Where Is Regeneron Pharmaceuticals Standing Right Now?
再生元製藥公司目前處於什麼位置？
- With a trading volume of 322,187, the price of REGN is down by 0.0%, reaching $1063.89.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 37 days from now.
- 交易量爲322,187，REGN的價格下跌了0.0%，達到了1063.89美元。
- 當前RSI值表明股票可能已經超買。
- 下一個盈利報告將在 37 天后發佈。
What The Experts Say On Regeneron Pharmaceuticals
專家對再生元製藥公司的看法如何？
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1195.6.
過去30天內，共有5名專業分析師對此股票發表了看法，設定平均目標價格爲$1195.6。
- An analyst from JP Morgan has decided to maintain their Overweight rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1150.
- Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Regeneron Pharmaceuticals, targeting a price of $1200.
- An analyst from RBC Capital downgraded its action to Outperform with a price target of $1229.
- An analyst from Argus Research persists with their Buy rating on Regeneron Pharmaceuticals, maintaining a target price of $1170.
- Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Regeneron Pharmaceuticals with a target price of $1229.
- JP摩根的一名分析師決定維持對再生元製藥公司的超配評級，目前股價目標爲1150美元。
- RBC Capital的一名分析師繼續保持看好再生元製藥公司的立場，目標價格爲1200美元。
- 來自RBC Capital的一位分析師下調其評級，將目標價設定爲1229美元人民幣。
- 雅運股份的一位分析師對再生元製藥公司的買入評級持續，並保持1170美元人民幣的目標價。
- RBC Capital的一位分析師在評估中一貫性地保持其買入評級的同時設置了1229美元人民幣的目標價。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
期權交易存在更高的風險和潛在的回報。精明的交易者通過不斷教育自己，調整策略，監測多種因子，並密切關注市場動向來管理這些風險。通過Benzinga Pro實時提醒了解關於最新的再生元製藥公司期權交易的信息。
譯文內容由第三人軟體翻譯。